Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States.

MLA

Fonseca, Rafael, et al. “Real-World Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States.” Mayo Clinic Proceedings. Innovations, Quality & Outcomes, vol. 7, no. 5, Sept. 2023, pp. 430–36. EBSCOhost, https://doi.org/10.1016/j.mayocpiqo.2023.07.001.

APA

Fonseca, R., Chinaeke, E. E., Gupta-Werner, N., Fu, A. Z., & Kaila, S. (2023). Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States. Mayo Clinic Proceedings. Innovations, Quality & Outcomes, 7(5), 430–436. https://doi.org/10.1016/j.mayocpiqo.2023.07.001

Chicago

Fonseca, Rafael, Eric E Chinaeke, Niodita Gupta-Werner, Alex Z Fu, and Shuchita Kaila. 2023. “Real-World Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States.” Mayo Clinic Proceedings. Innovations, Quality & Outcomes 7 (5): 430–36. doi:10.1016/j.mayocpiqo.2023.07.001.